Communiqués Appili Therapeutics Inc.

Actions

APLI

CA03783R1073

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. 15:36:20 02/09/2026			Varia. 5j.	Varia. 1 janv.
0,0100 ^CAD	-33,33%		-33,33%	-60,00%

14/08	Appili Therapeutics Inc. publie ses résultats pour le premier trimestre clos le 30 juin 2026	CI
04/07	Appili Therapeutics Inc. reçoit un avis de résiliation pour convenance du National Institute of Allergy and Infectious Diseases concernant le contrat du programme VXV-01	CI

Communiqués

17/08	Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027	AQ
14/08	Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2027	NE
06/07	Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program	AQ
04/07	Appili Therapeutics Announces Receipt from NIAID of a Notice of Termination for Convenience on the Contract for the VXV-01 Program	AQ
27/06	Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results	AQ
30/03	Appili Therapeutics to Exhibit at World Vaccine Congress Washington	AQ
18/02	Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement	AQ
13/02	Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026	AQ
18/12	Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement	AQ
13/11	Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026	AQ
05/11	Appili Therapeutics Announces Proposed Non-Brokered Private Placement	AQ
22/10/25	Appili Therapeutics to Attend BARDA Innovation Symposium 2025	AQ
01/10/25	Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01	AQ
24/09/25	Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders	AQ
23/09/25	Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders	AQ
09/09/25	Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference	AQ
14/08/25	Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026	AQ
06/08/25	Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine	AQ
26/06/25	Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results	AQ
01/05/25	Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia	AQ
28/04/25	Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™	AQ
17/02/25	Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025	AQ
20/11/24	Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.	AQ
18/10/24	Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek 2024	AQ
17/10/24	Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024	AQ